

Pulmonary care in SMA: what the spine surgeon should know

Mary Schroth MD

Professor, Pediatric Pulmonology

University of Wisconsin School of Medicine and Public Health, Madison UW Health American Family Children's Hospital Director, Pediatric Pulmonary Center Training Grant mschroth@wisc.edu

Cure SMA Medical Director Chair, Cure SMA Medical Advisory Council mary@curesma.org



Disclosures

- Cure SMA Paid Medical Director
- AveXis Advisory Committee Member
- Biogen Idec Advisory Committee Member
- IONIS Pharmaceuticals Advisory Committee Member
- HHS/HRSA/Maternal Child Health Bureau Pediatric Pulmonary Center Training Grant



Learning Objectives

Participants will:

- 1. Identify the effects of neuromuscular weakness on respiratory pathophysiology and the resulting respiratory complications.
- 2. Describe management strategies that optimize respiratory function.
- 3. Consider the impact of gene modifying therapy on SMA.



Standard of Care Guidelines SMA

Special Issue Article

Consensus Statement for Standard of Care in Spinal Muscular Atrophy

Ching H. Wang, MD, PhD, Richard S. Finkel, MD, Enrico S. Bertini, MD, Mary Schroth, MD, Anita Simonds, MD, Brenda Wong, MD, Annie Aloysius, MRCSLT, HPC, Leslie Morrison, MD, Marion Main, MCSP, MA, Thomas O. Crawford, MD, Anthony Trela, BS, and Participants of the International Conference on SMA Standard of Care

Encompasses:

- Diagnosis
- Respiratory Care
- GI and Nutrition
- Musculoskeletal
- Palliative Care

Journal of Child Neurology Volume 22 Number 8 August 2007 1027-1049 © 2007 Sage Publications 10.1177/088307305788 http://jcn.sagepub.com hosted at http://online.sagepub.com

Wang C et al, J. Child Neurol 2007; 22:1027.



Spinal Muscular Atrophy

- Multi-organ involvement
 - Musculoskeletal
 - Respiratory
 - GI and nutrition
 - Bone health
 - Autonomic
 - Mental health
 - Cardiac
- It takes a village...





Neuromuscular Disorders

• Cause of death is usually respiratory failure.

SMA Pulmonary Natural History







Spinal Muscular Atrophy

- <u>Progressive</u> autosomal recessive genetic disorder
 - affects the motor neurons of the anterior horn cells.







SMA Genetics

- Carrier rate: 1 in 50
- Incidence estimate: 1/6,000-1/10,000 live births ٠
- Diagnose by gene mutation testing
 - -Chromosome 5q (>95%) Homozygous deletion of SMN1 exon 7 and/or exon 8 OR Gene conversion of SMN1 to SMN2-like
 - -Remaining 5% have point mutation
- Most common lethal genetic disease of children under 2 yo





SMA Clinical Manifestations

- Symmetric muscle weakness
- Wasting of voluntary muscles
 - Proximal muscles weaker than distal muscles
 - Legs weaker than arms
 - Tongue fasciculations
 - Absent deep tendon reflexes
 - Weak intercostal muscles in SMA type I and II
- Normal intellect and sensation
- "Bright-eyed hypotonic baby"





Clinical Classification of SMA

SMA TYPE	Incidence	Age of Onset	Motor Milestones	Ave Age of Death (limited interventions)	
I	50-60%	< 6 months	Non sitter	< 2years	
	25%	< 18 months	Sitter	2 nd - 3 rd decade	
III	10%	> 18 months	Stander/walker	Normal life expectancy	
IV	5%	Adolescent or Adult onset	Retain walking, muscle pain	Normal life expectancy	



Changing Natural History of SMA Type I

- Comparison of children with SMA type I born between:
 - 1980-1994 (n=65)
 - 1995-2006 (n=78)
- Subjects identified using the Indiana University International SMA Patient Registry
- Surveyed by mail with follow up questions.

Oskoui M et al, Neurol 2007; 69:1931.



Kaplan–Meier survival plots of Spinal Muscular Atrophy type 1









Baioni MTC, et al, J Pediatr (Rio J). 2010;86(4):261-270



Phenotype/Genotype (cont.)

SMN2 gene copy number varies in the population and modifies disease severity

<i>SMN 2</i> copy #	SMA 1	SMA 2	SMA 3	
1	7	0	0	
2	73	11	4	
3	20	82	51	
4	0	7	45	
Total	100%	100%	100%	

Courtesy of Thomas Crawford MD, Presentation at Cure SMA Annual Conf 2015

2017 SMA Drug Discovery Pipeline

				ND		A		
BASIC RESEARCH SEED IDEAS	PRECLINICAL: DISCOVERY			CLINICAL DEVELOPMENT			FDA APPROVAL	TO PATIENTS
	IDENTIFICATION	OPTIMIZATION	SAFETY & MANUFACTURING	PHASE 1	PHASE 2	PHASE 3		
-Spinraza							Dec 2016	
· AVXS-101 (systemic)								
-Olesaxime								
-CK-2127107								
LMI070								
-R67916								
AVXS-101 (CNS-delivered)								
SRK-015 (muscle drug)								
-Small Molecule								
ACE-249 (muscle drug)								
-CNS Gene Therapy								
Gene Therapy								
-Small Molecule								
Morpholino ASO								
Small Molecules								
Small Molecule								
Small Molecule								
-p38aDMAPK Inhibitor								
JNK Inhibitor								

IND = Investigational New Drug Last updated: May 2017 NDA = New Drug Application





Gene Modified SMA







Respiratory Management





Complications of Respiratory Muscle Weakness in SMA

- 1. Impaired cough
 - Poor clearance of lower airway secretions
- 2. Hypoventilation during sleep
 - hypercarbia
 - hypoxemia
- 3. Recurrent infections that contribute to muscle weakness.
- 4. Chest wall and lung underdevelopment in SMA type I and II

Wang C et al, J Child Neurol 2007; 22:1027.



Chest Wall Changes



Schroth, Pediatrics, 2009; 123 Suppl 4, S245-9.





NMD Lung Function Loss

VIRAL RESPIRATORY INFECTIONS

- Rhinovirus RSV Parainfluenza Influenza Etc...
- Transient muscle function weakness
 Mier-Jedrzeiowicz A et al, Respiratory muscle weakness during upper respiratory tract infections, ARRD 1988 Jul;138(1):5.
- IMPACT:
 - Increased muscle weakness
 - Copious airway secretions
 - More difficulty breathing
 - Risk for respi



Perioperative Care

- Respiratory Support
- Nutrition



Breathing Basics

- Secretion mobilization
- Cough Augmentation
- Respiratory support





Secretion Mobilization

 Manual Chest Physiotherapy or Mechanical Percussion







 Postural Drainage







Intrapulmonary Percussive Ventilation

High Frequency Chest Wall Oscillation

Vest







Cough Mechanism

3 Phases of a cough

- 1. Inspiratory phase
- 2. Closure of vocal cords/contraction of expiratory muscles
- 3. Opening of the vocal cords



Mechanical Insufflation-Exsufflation: Cough Machines



Respironics Cough Assist™ CA-3000







Hill-Rom Vital Cough™

Respironics Cough Assist™ T70



Cough Machine

- SETTINGS to use by mask, mouth piece, tracheostomy tube or endotracheal tube.
 - INSPIRATORY
 - Start at +25-30, increase to +40 cm H_2O for 1-2 sec.
 - EXPIRATORY
 - Start at -25-30, increase to -40 cm H₂O for 1-2 sec.
 - PAUSE TIME
 - 1-2 sec.
 - Perform 4 sets of 5 breaths





Pulse Oximetry

- Use to guide airway clearance therapy
- Acutely decreased oximetry (< 95% while AWAKE)
 - suggests increased secretions, mucus plugging, or atelectasis.
 - may be the first sign of respiratory compromise.
- < 95% while ASLEEP
 - suggests hypoventilation or mucus plugging.

OXYGEN IS A LAST RESORT AFTER ALL OTHER INTERVENTIONS ARE OPTIMIZED!

FRC Relative to Position

Respiratory Support Options

- Used during sleep or at least 6 hours per day
- Non-invasive ventilation
 - Bilevel positive airway pressure
 - Mechanical ventilation
- Invasive ventilation
 - Tracheotomy with Mechanical ventilation

Chronic Respiratory Failure: Bilevel Positive Airway Pressure Effects

- Sustained reduction of daytime PaCO2
 - 3 Theories for NIV effect:
 - Rests chronically fatigued respiratory muscles
 - Reverses micro-atelectasis
 - Alters the CO2 "set point"

Mehta and Hill, Am J Respir Crit Care Med 2001; 163:540

Positive Pressure Ventilation Devices

1. Bilevel positive airway pressure devices Non- invasive only

CPAP is NOT INDICATED for Neuromuscular hypoventilation

Non Invasive Bilevel Positive Airway Pressure

- Goals:
 - Ventilation
 - Decrease work of breathing rest respiratory muscles
 - » Decrease belly breathing
 - » Normalize heart rate during sleep
 - Improve chest wall expansion

Indications for Positive Pressure Ventilation

- Sleep study:
 - Hypoventilation (↓ SpO2, ↑ pCO2)
 - Obstructive sleep apnea
- Specific to NMD
 - Respiratory failure during a viral illness
 - Recurrent pneumonia or atelectasis
 - Post-operative care

Chest Wall Development After NIV

6 mths

18 mths

Courtesy of A. Simonds, Royal Brompton Hospital, UK

Nasal Masks

Respironics Wisp Pediatrics

Infant to 2 yo:

- Respironics Wisp Pediatrics
- AG Industries Nonny

Over 2 years old:

- ResMed Pixi
- Sleepnet MiniMe 2
- Respironics Wisp
- Fisher & Paykel Eson
- Fisher & Paykel Zest

AG Industries Nonny, Size Small Child, AG-PEDKIT-S

Invasive Ventilation

- Tracheostomy placement
 - Not an acute intervention
 - Involve primary medical team in decision making
- Indications
 - 24 hour per day NIV dependent
 - Frequent cyanotic episodes or respiratory instability on NIV
 - NIV intolerance
 - Failure to extubate
 - Patient preference

Wang C et al. J. Child Neurol 2007; 22:1027.

Positive Pressure Ventilation

- Goals during sleep:
 - Respiratory muscle rest
 - Synchronization
 - Chest wall expansion
- Recommended modes:
 - PC (Pressure control) guaranteed inspiratory time with back up rate
 - ST (spontaneous timed) with back up rate
 - PC-AVAPS (average volume assured pressure support) targeted tidal volume within IPAP range
 - IPAPmin must be high enough to support ventilation
- Backup respiratory rate required

Non Invasive Bilevel Positive Airway Pressure

- IPAP: 14-20 cm of H₂0
- EPAP: 4-6 cm of H₂0
- Respiratory Rate: high enough to capture breathing efforts and rest during sleep.
- Inspiratory Time: Longer time preferred to maximize inflation 1.2 seconds
- Rise time: time between exhalation and rise to peak inspiratory pressure (IPAP)

GI and Nutrition Complications

- Dysphagia
 - Aspiration
 - Weight loss
- Gastroesophageal reflux
- Gastroparesis
- Constipation
 - Decreased appetite
 - NIV intolerance
- Poor weight gain
- Obesity

GI and **Nutrition Complications (cont.)**

- Large insensible fluid losses
 - Perspiration
 - Suctioning oral/nasal secretions
 - Hospital I&Os are never balanced
 - 1.2x maintenance

GI and Nutrition Complications SMA Specifically

- Abnormal fatty acid oxidation
 - Abnormal dicarboxylic aciduria in response to fasting
 - Avoid high fat diet (Max: 20% of calories)
 - Ketosis and ketonuria with fasting/dehydration
 - Avoid fasting in weakest group: anyone with tube feeds

Tein et al. Fatty Acid Oxidation Abnormalities in Childhood-Onset Spinal Muscular Atrophy: Primary or Secondary Defect(s)? Pediatr Neurol 1995;12:21-30.

Respiratory Therapy NMD Protocol

- Scoring system to guide frequency of airway clearance and time off ventilation if not 24 hour dependent
- Aggressive airway clearance:
 - Cough assist machine while intubated
 - Secretion mobilization techniques
 - Postural drainage if not ETT intubated

Extubation

Extubate when the patient is:

- 1. Afebrile
- 2. Not requiring supplemental O2
- 3. CXR is without atelectasis or infiltrates
- 4. Minimal respiratory depressants
- 5. Airway suctioning is 1 time/hour or less
- 6. Motor strength and alertness approaching baseline

Extubation (cont.)

- Extubate from reasonable settings:
 - respiratory rate similar to the optimal baseline positive pressure device respiratory rate
 - pressures that approximate BiPAP IPAP (15-20) and EPAP (3-6)
 - room air
 - Wean to use during sleep
- <u>Avoid</u> low ventilator rates through ET tube especially during sleep
 - \Rightarrow atelectasis/fatigue.
- Continue aggressive airway clearance post extubation.
 - Increased airway secretions for 24 hours post extubation

Other Complications of NMD

- Osteopenia poor bone health
- Scoliosis
- Joint contractures
- Rapid fatigue
- Pain
- Depression

UW Pediatric Neuromuscular Disorder Program

- Respiratory Care
 - Physician/Nurse practitioner
 - Respiratory care practitioners
- Neurology
 - Physician/Nurse practitioner
- Care coordination
 - Clinic coordinator
 - Case Manager
- Palliative Care
 - Physician/Nurse practitioner
- Genetic Counselor
- Nutritionist
- Social Worker

- Orthopedic and Rehabilitation Medicine Services
 - Physician/Nurse practitioner
 - Physical Therapist
 - Occupational Therapist
 - Speech Therapist
 - Orthotist
 - Vocational Rehabilitation Coordinator
- Cardiology
 - Physicians
 - Nurse Practitioner

Summary

- The respiratory complications of neuromuscular disease include:
 - Hypoventilation during sleep and with disease progression while awake
 - Compromised airway secretion clearance
- Supplemental oxygen is not the answer
- Use positive pressure ventilation at settings to ventilate and rest the patient during sleep.

Summary

- Perioperative care includes optimization of pulmonary status and nutrition status.
 - Pulmonary consultation
 - Nutrition consultation

Summary

- The natural history of many neuromuscular diseases are evolving with longer survival and improved care options.
- Gene modifying therapy is creating another form of SMA.
- Interdisciplinary management is essential.

Additional Information

- Cure SMA website: <u>www.curesma.org</u>
- SMA Foundation website: www.smafoundation.org
- Muscular Dystrophy Association website: <u>www.mdausa.org</u>

Questions/ Comments/ Discussion

